Pharmaceutical care in an inpatient pediatric hematopoietic stem cell transplant service

Prot-Labarthe, Sonia; Therrien, Roxane; Demanche, Colette; Larocque, Diane; Bussières, Jean-François

doi:10.1177/1078155208093929

Cited by 19 publications

(19 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Among the studies included, four were performed in HSCT outpatient clinics, 8,9,19,20 two in HSCT inpatient clinics 21,22 and one in both settings. 23 Regarding the type of transplantation, four publications included both patients undergoing autologous and allogeneic HSCT; 20–23 the others included only patients undergoing allogeneic HSCT. 8,19 Concerning the year of publication, most articles were published in the last five years.…”

Section: Resultsmentioning

confidence: 99%

“…8,19 Concerning the year of publication, most articles were published in the last five years. 8,9,19,22,23 Four surveys were conducted in North America, 19–21,23 one in South America, 9 one in Asia, 22 and one in Oceania. 8…”

Section: Resultsmentioning

confidence: 99%

“…Only one publication reached a score considered to be good, 22 three manuscripts were classified as medium quality, 8,9,23 and the remaining three were rated as poor quality. 19–21…”

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

Clinical pharmacists’ contributions to hematopoietic stem cell transplantation: A systematic review

Barboza-Zanetti¹,

Barboza-Zanetti

Rodrigues-Abjaude³

et al. 2018

J Oncol Pharm Pract

View full text Add to dashboard Cite

Aims The goal of the present review was to identify studies that assess how pharmaceutical services contribute to hematopoietic stem cell transplantation (HSCT). Methods We conducted a systematic literature review of published studies describing results from clinical services provided by pharmacists working with HSCT, conducted according to PRISMA guidelines ( PROSPERO registration number CRD42017062391). A search strategy was applied within PubMed, CENTRAL, EMBASE, SCOPUS, and LILACS databases in April 2017. Inclusion criteria were observational or experimental studies that addressed the following research question: "What are a clinical pharmacist's main contributions to HSCT?" The quality of selected studies was evaluated using the Downs and Black checklist. Results We identified 1838 studies, and seven were included in the systematic review. The results indicated that clinical pharmacy is useful during HSCT treatment within both inpatient and outpatient settings. Pharmaceutical contributions identified included management of pharmacotherapy-related problems, participation in discussions with clinical teams, drug reconciliation, patient and team education regarding pharmacotherapy, preparation of guidelines and educational materials, and evaluation of medication adherence. These activities favored the control and prevention of pharmacotherapy-related problems, the maintenance of immunosuppressive serum levels, improvement in patients' clinical and nutritional status, facilitated medication adherence, and provided economic and humanistic gains. Conclusions Despite the small number of articles discussing the topic under analysis, the results were unanimous in confirming the positive impact of pharmacists' contributions to clinical practice for HSCT.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Clinical pharmacists’ contributions to hematopoietic stem cell transplantation: A systematic review

Barboza-Zanetti¹,

Barboza-Zanetti

Rodrigues-Abjaude³

et al. 2018

J Oncol Pharm Pract

View full text Add to dashboard Cite

show abstract

“…In one of the studies conducted in the pediatric HSCT units, clinical pharmacists' involvement had significant contribution to the development of the protocols for the prevention of adverse effects and drug interactions through the adjustment of drug doses and the selection of appropriate supportive treatments (such as pain management and mucositis prevention) for complications (6). During the seven-month period of our study, consultancy on different issues was provided by the pharmacist to the physicians.…”

Section: Discussionmentioning

confidence: 99%

“…The exponential increase in HSCT activities has led to the inclusion of pharmacists in HSCT practice throughout the world. Clinical pharmacists have become critical members of HSCT teams for the last 10 years (6). The presence of a clinical pharmacist in the HSCT team is an approach aimed at improving the quality of care, through their contribution to detection, prevention and management of drug-related problems (DRPs) (8,9).…”

Section: Introductionmentioning

confidence: 99%

Evaluation of Drug-Related Problems in a Pediatric Bone Marrow Transplantation Unit Identified by a Clinical Pharmacist in-training in a 7-Month Period

Özdemir¹,

Çeliker²,

Kuşkonmaz³

et al. 2020

Clinical and Experimental Health Sciences

View full text Add to dashboard Cite

Objective: This cross sectional study was performed to demonstrate the importance of clinical pharmacists' participation in pediatric hematopoietic stem cell transplantation patient management with regards to the detection, prevention, and management of drug-related problems. Methods:The study was carried out from 1st October 2015 to 1st May 2016 in a pediatric bone marrow transplantation unit of a tertiary care hospital. The inpatients and outpatients between 0 to 18 years of age were included and the patients were monitored and evaluated for drugrelated problems (interactions, side effects, preparation, and administration). A clinical pharmacist-in-training made recommendations to the physicians and the nurses on the problems that were identified.Results: Twenty inpatients and twenty-two outpatients were monitored during the study. In total, 245 problems were identified in the inpatients, 37.14 % of which were drug-related; 33 % of the drug-related problems were the side effects of cyclosporine. Eleven recommendations on drug-related problems were made to the physicians and six of them were for the problems identified in the inpatient services with regards to drug dosing and administration. Five recommendations regarding total parenteral nutrition, drug incompatibility, drug administration from the feeding tube, and drug side effects were made to the nurses. Twenty-nine information on the dosing, side effects, incompatibilities, administration, and preparation of the drugs, were given by the pharmacist to the physicians and the nurses.Conclusion: Clinical pharmacists' participation will improve the detection and the management of drug-related problems in pediatric hematopoietic stem cell transplantation units in Turkey.

show abstract

Pediatric drug-related problems: a multicenter study in four French-speaking countries

et al. 2012

View full text Add to dashboard Cite

show abstract

Pharmaceutical care in an inpatient pediatric hematopoietic stem cell transplant service

Cited by 19 publications

References 15 publications

Clinical pharmacists’ contributions to hematopoietic stem cell transplantation: A systematic review

Clinical pharmacists’ contributions to hematopoietic stem cell transplantation: A systematic review

Evaluation of Drug-Related Problems in a Pediatric Bone Marrow Transplantation Unit Identified by a Clinical Pharmacist in-training in a 7-Month Period

Pediatric drug-related problems: a multicenter study in four French-speaking countries

Contact Info

Product

Resources

About